2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 622

Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Dry Eyes
Abstract Number: 623

Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity
Abstract Number: 624

Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Oral Disease Management: Caries Prevention
Abstract Number: 625

Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease
Abstract Number: 626

Efficacy of Belimumab and Targeting of Rheumatoid Factor Positive B-Cells in Sjögren’s Syndrome: Follow-up of the Open-Label Phase II Study
Abstract Number: 627

Clinical Subsets and Presenting Features in Primary Sjögren’s Syndrome: Results from a Single Center Inception Cohort Study
Abstract Number: 628

Poor Prognosis of Patients with Primary Sjögren Syndrome Who Fulfilled at Diagnosis the Classification Criteria for Concomitant Cryoglobulinemic Vasculitis
Abstract Number: 629

Salivary Gland Ultrasonography As an Useful Tool to Distinguish Patients with Sjögren’s Syndrome at Risk for Non-Hodgkin’s Lymphoma Development
Abstract Number: 630

Can Extraglandular Manifestations Differentiate Primary Sjögren’s Syndrome from Sjögren’s-Systemic Lupus Erythematosus Overlap Syndrome?
Abstract Number: 631

Usefulness of the Minimally-Invasive Minor Salivary Gland Biopsy in Patients Presenting with Sicca Syndrome: Prospective Evaluation of 200 Patients
Abstract Number: 632

Isolated Atrioventricular Block of Unknown Origin in the Adult and Autoimmunity: Diagnostic and Therapeutic Considerations Exemplified By Three Anti-Ro/SSA-Associated Cases
Abstract Number: 633

Anti-Centromere Antibodies Are Associated with More Severe Exocrine Glandular Dysfunction in Primary Sjögren’s Syndrome: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Abstract Number: 634

Big Data International Primary Sjögren Syndrome Registry: Baseline Characterization and Diagnostic Approach in 6047 Patients Fulfilling the 2002 AE Criteria
Abstract Number: 635

Seronegative Sjögren’s Syndrome Is Associated with a Higher Frequency of Patient-Reported Neuropathic Pain: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Abstract Number: 636

Utility of IgA Anti-Alpha-Fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies As Substitute Immunological Criterion for Sjögren’s Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].